April 22, 2022
1 min read
Save
FDA approves BLA resubmission for daxibotulinumtoxinA injection
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Revance Therapeutics announced the FDA has accepted its Biologics License Application resubmission for daxibotulinumtoxinA for injection for the treatment of moderate to severe glabellar lines, according to a company press release.
The FDA designated the company’s biologics license application as a class 2 resubmission with a six-month review period and a required reinspection of its manufacturing facility.
The company was provided a prescription drug user fee act goal date of September 8, 2022, according to the release.
Published by:
Sources/Disclosures
Collapse
Source:
Press release
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.